Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The AAPS Journal|February 16, 2020
Model Averaging in Viral Dynamic ModelsAntonio Gonçalves, France Mentré, Annabelle Lemenuel-Diot, et al.
Clinical Pharmacology and Therapeutics|November 21, 2022
A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated InterferonSelma El Messaoudi, Annabelle Lemenuel-Diot, Antonio Gonçalves, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 8, 2006
Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysisAnnabelle Lemenuel-Diot, Christian Laveille, Nicolas Frey, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2007
Evaluation of uncertainty parameters estimated by different population PK software and methodsCéline Dartois, Annabelle Lemenuel-Diot, Christian Laveille, et al.
Antiviral Therapy|January 11, 2018
A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitorLaetitia Canini, Annabelle Lemenuel-Diot, Barbara J Brennan, et al.
Antiviral Therapy|November 12, 2015
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infectionLaetitia Canini, Jeremie Guedj, Anushree Chatterjee, et al.
Journal of Viral Hepatitis|October 19, 2020
What drives the dynamics of HBV RNA during treatment?Antonio Gonçalves, Annabelle Lemenuel-Diot, Valérie Cosson, et al.
Antiviral Therapy|October 17, 2014
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCVLaetitia Canini, Anushree Chatterjee, Jeremie Guedj, et al.
British Journal of Clinical Pharmacology|November 4, 2015
Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis CBarbara J Brennan, Annabelle Lemenuel-Diot, Eric Snoeck, et al.
Clinical Pharmacology and Therapeutics|February 1, 2021
How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus DrugValérie Cosson, Sheng Feng, Felix Jaminion, et al.
Pageof 3